Construction of Immune-Associated Nomogram for Predicting the Recurrence Survival Risk of Stage I Cervical Cancer

Figure 5

Immune gene risk score analysis of 258 stage I CC samples in the GEO dataset. (a) Metabolic gene risk score distribution against the rank of risk score. Median risk score was adopted as the cutoff point. (b) Recurrence-free survival status of stage I CC patients. (c) Heatmap of 8 immune gene expression profiles of stage I CC patients.

(a)

(b)

(c)